Articles By Rob Wright

  1. NeoStem's CEO Spearheads Stem Cell Research Collaboration With The Roman Catholic Church 10/31/2013

    Robin Smith, M.D., CEO of NeoStem, strikes up a conversation about stem cell research benefits with one of the largest, wealthiest organizations that are very publicly against embryonic stem cell research – the Roman Catholic Church.

  2. How To Take Charge Of Your Public-Private Partnerships 10/31/2013

    The process of creating a public-private partnership (P3) can be very challenging not only due to the size of the organizations involved (NIH), but the navigation of academic and government-institution policies and procedures for brokering a partnership can be a labyrinth.

  3. From Obscurity To Innovation Engine – The Evolution Of Specialty Pharma 10/31/2013

    By 2018, it is estimated specialty drug spend will surpass traditional drug spend, and in three years market research project 7 of the top 10 bestselling drugs will be specialty drugs. With such as staggering growth how will insurance companies be able to afford to pay for such lifesaving treatments.

  4. Drug Take-Back Programs – Coming To A Municipality Near You 10/2/2013

    While some believe self-funded regulatory agencies to be a good thing, others feel it allows industry to have major leverage over FDA policy decision making.

  5. The Art Of The Turnaround In Pharma 10/2/2013

    Leonard Jacob M.D., Ph.D., a 35-year pharma industry veteran, believes that when assessing a company for growth, although the management team and financials are two common factors to consider, the most important is product opportunity.

  6. Does Your Pharma CMO Deliver On Its Promises After Being Acquired? 10/1/2013

    I first met Mark Bamforth, the president and CEO of Gallus BioPharmaceuticals, at a conference shortly after he had acquired/founded his CMO in St. Louis. The company was so new many of the employees at the event didn’t even have business cards.

  7. Pfizer's Hybrid Approach To Implementing Continuous Manufacturing Processes 8/30/2013

    Kevin Nepveux, VP of global technology services with in Pfizer Global Supply shares his insights about continuous manufacturing and how Pfizer is deploying continuous and batch processes as a hybrid approach toward improving manufacturing efficiencies. Kevin Nepveux says “I think one of the best ways to go about implementing CM processes is to develop the analytics in line with the application.”

  8. Private Or Public? Not Really Even A Question In Life Sciences? 8/29/2013

    When launching a start-up in the life sciences industry the question of going public or private could be a struggle. A key driver for the decision to go public is the availability of funding sources and management’s experiences and relationships, says Punit Dhillon, president and CEO of OncoSec Medical Inc.

  9. Can India Achieve cGMP For Vaccines? Does It Matter? 7/31/2013

    Bharat Biotech pledged to sell Rotovac for the rotavirus for $1 a dose to compete with GSK and Merck, if they make it cheaper can they make it safer?

  10. Takeda's Approach To Becoming A Global Player In The Vaccine Market 7/31/2013

    In 2008 Takeda Pharmaceuticals took aim at becoming a global pharmaceutical company by making a number of strategic moves, such as the dissolution of the 23-year, 50/50 joint venture with Abbott, known as TAP Pharmaceuticals, and acquiring Millennium Pharmaceuticals (2008) and Nycomed. These changes strengthened Takeda’s position in two of the largest pharmaceutical markets outside of Japan (U.S. and EU), placing it on the verge of being the first Japanese company to be listed among the 10 largest pharmaceutical companies in the world. With 2012 net sales of $18.4 billion, Takeda ranks twelfth, up four spots from the previous year. What will get them to the next level?